Meridian earns CLIA moderate complexity rating for Strep tests

03/20/2013 | GenomeWeb Daily News (free registration)

The FDA has granted moderate complexity status for Meridian Bioscience's Group A and Group B Streptococcus tests under the agency's Clinical Laboratory Improvement Amendments program. The assays, which already have been cleared by the FDA and run on the company's illumigene platform, originally were classified as high complexity tests.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID